论文部分内容阅读
目的观察吉西他滨联合紫杉醇(均为抗癌药)治疗老年晚期非小细胞肺癌的疗效与安全性。方法老年晚期非小细胞肺癌35例,吉西他滨1000 mg加入生理盐水250 mL,静滴45 min;紫杉醇120 mg加入生理盐水250 mL,静滴2h,每3~4周为1周期,其中33例完成3周期化疗。结果在33例中,完全缓解2例(6.06%),部分缓解15例(45.45%),无变化9例(27.27%),疾病进展7例(21.21%),总有效率为51.52%;中位生存时间10个月,中位肿瘤进展时间8个月。不良反应主要表现为骨髓抑制、肝功能损害、脱发、粘膜炎及周围神经毒性。结论吉西他滨联合紫杉醇治疗老年晚期非小细胞肺癌疗效较好,毒性反应较轻。
Objective To observe the efficacy and safety of gemcitabine combined with paclitaxel (all anticancer drugs) in the treatment of elderly patients with advanced non-small cell lung cancer. Methods 35 elderly patients with advanced non-small cell lung cancer were treated with gemcitabine 1000 mg added with 250 mL normal saline and intravenous infusion for 45 min. Paclitaxel 120 mg was added with normal saline 250 mL, intravenously for 2 h, every 3 to 4 weeks was 1 cycle, 33 of which were completed. 3 cycles of chemotherapy. Results Among the 33 patients, 2 patients (6.06%) achieved complete remission, 15 (45.45%) achieved partial remission, 9 (27.27%) did not change, and 7 (21.21%) patients developed disease. The total effective rate was 51.52%; The survival time was 10 months, and the median tumor progression time was 8 months. The main adverse reactions were bone marrow suppression, liver damage, hair loss, mucositis and peripheral nerve toxicity. Conclusion Gemcitabine combined with paclitaxel is effective in the treatment of elderly patients with advanced non-small cell lung cancer, and the toxicity is lighter.